


Docket no. MERZ 48 PCT US



CERTIFICATE OF MAILING  
UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313 on August 15, 2006.  
By: *[Signature]*

\*\*\*\*\*

Applicant : Walter MAGERL, et al.  
Serial No. : 10/566,106  
Filed : January 26, 2006  
Title : Use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity.  
Art Unit :

\*\*\*\*\*

Honorable Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313

COMMUNICATION COVERING TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT UNDER 37  
CFR §§ 1.97 AND 1.98

Sir:

Herewith, in accord with the foregoing regulations, please find an Information Disclosure Statement which, it is respectfully submitted, should materially advance and accelerate the prosecution of the above-identified application. It is respectfully requested that the information be expressly considered during the prosecution of this application and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

As will be noted, this Information Disclosure Statement calls a number of references, which might be considered relevant, to the attention of the Examiner. The fact that these are in fact "Prior Art" is, however, not admitted.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR § 1.98 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,  
THE FIRM OF HUESCHEN AND SAGE


By: *[Signature]*  
G. PATRICK SAGE

Dated: August 15, 2006  
Customer No.: 25,666  
Seventh Floor, Kalamazoo Building  
107 West Michigan Avenue  
Kalamazoo, MI 49007  
(269) 382-0030

Enclosure: Form PTO-1449 and Accompanying References and Postal Card Receipt.

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.

PTO-1449	ATTY. DOCKET NO. MERZ 48 PCT US	SERIAL NO. 10/566,106
LIST OF PRIOR ART CITED BY APPLICANT	APPLICANT Walter MAGERL, et al.	
SHEET <u>1</u> OF <u>1</u>	FILING DATE January 26, 2006	GROUP



#### U.S. PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO

#### OTHER PRIOR ART

	Anton BESPALOV, et al., "Prolongation of morphine analgesia by competitive NMDA receptor antagonist D-CPPene (SDZ EAA 494) in rats" European Journal of Pharmacology, Vol. 351, Pg. 299-305, 1998.
	Susan CARLTON, et al., "Treatment with the NMDA antagonist Memantine attenuates nociceptive responses to mechanical stimulation in neuropathic rats" Neuroscience Letters, Vol. 198, Pg. 115-118, 1995.
	Sandra Chaplan, et al., "Efficacy of spinal NMDA receptor antagonism in formalin Hyperalgesia and nerve injury evoked allodynia in the rat" Journal of Pharmacology & Experimental Therapeutics, Vol. 280 No. 2, Pg. 829-838, 1997.
	Elon EISENBERG, et al., "The clinically tested N-methyl-D-aspartate receptor antagonist Memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy" Neuroscience Letters, Vol. 187, Pg. 17-20, 1995.
	Yan IN KIM, et al., "NMDA receptors are important for both mechanical and thermal allodynia from peripheral nerve injury in rats" NeuroReport, Vol. 8, Pg. 2149-2153, 1997.
	A.A. MALYSHKIN, et al., "Lack of synergism between NMDA receptor channel blockers and morphine or clonidine in rats with tactile allodynia" Program NO. 589.6, 2003 Abstract, Viewer/Itinerary Planner, Washington, DC Society for Neuroscience, 2003 Online.
	Ivan O. MEDVEDEV, et al., "Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain" NEUROPHARMACOLOGY, Vol. 47, Pg. 175-183, 2004.

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.